Introduction {#S1}
============

Hypertension (HTN) is a significant risk factor for cardiovascular morbidity and mortality. However, even after accounting for the beneficial effects of blood pressure reduction on cardiovascular events, cardiovascular risk remains elevated despite intensive lowering of blood pressure.^[@R1]^ Metabolic abnormalities, including adverse cholesterol and triglycerides (TG) profiles, are frequent comorbid findings with HTN and may contribute to the residual cardiovascular disease (CVD) risk associated with antihypertensive therapy. Thiazide diuretics are recommended as first-line therapy for the treatment of HTN.^[@R2]^ Loop diuretics are a mainstay in the treatment of heart failure and are frequently used in patients with HTN complicated by renal insufficiency to control volume retention. However, there is little evidence to support a survival benefit with the use of loop diuretics.^[@R3]^ Both thiazide and loop diuretics have been associated with worsening fasting lipid concentrations,^[@R4]--[@R6]^ which may dampen the salutary effects of antihypertensive therapy in some patients. While there have been studies identifying genetic sources of inter-individual blood pressure response to primarily thiazide diuretic therapy,^[@R7]--[@R11]^ there is little literature regarding the interactions of diuretics with genetic variants on blood lipid concentrations.^[@R12]^

A meta-analysis of 56 randomized, placebo-controlled trials of diuretic monotherapy for the treatment of HTN, including both European-ancestry (EA) and African-ancestry (AA) individuals, showed that diuretic therapy was associated with average changes of 0.29 mmol/L for total cholesterol (TC), 0.24 mmol/L for low-density lipoprotein cholesterol (LDL), −0.02 mmol/L for high-density lipoprotein cholesterol (HDL), and 0.35 mmol/L for TG.^[@R13]^ Some long-term studies have suggested that effects of diuretics on lipid concentrations waned after one year.^[@R14],[@R15]^ A retrospective analysis of the Systolic Hypertension in the Elderly Program (SHEP) showed persistent, albeit more modest, increases in lipid concentrations (three-year change in TG: 0.28 ± 0.86 mmol/L with chlorthalidone vs. 0.09 ± 0.71 mmol/L with placebo, *P*\<0.001) when a cohort was randomized to a thiazide-like diuretic or a placebo;^[@R16]^ however, these results may have been affected by the use of non-diuretic antihypertensive drugs (atenolol and reserpine). Notably, the larger standard deviations suggest that an underlying genetic component may explain the high variability in individual's lipid response to diuretic therapy.

Although the genetic underpinnings of fasting cholesterol and TG concentrations have been well-described, single nucleotide variants (SNVs) identified through genome-wide association studies (GWAS) explain only \~10--12% of heritability.^[@R17]^ Some studies have shown that the response of lipid concentrations to diuretics is significantly greater in AA than in EA individuals,^[@R13]^ further suggesting the modulating effect of genetic architecture. Unfortunately, most long-term studies were based on either almost exclusively EA subjects^[@R15]^ or studies including individuals of multiple ancestries where response by ancestry was not characterized.^[@R14]^ The purpose of this investigation was to determine whether common genetic variants modify the effect of diuretic use on blood lipid concentrations in persons of European and African ancestry. Exposure to thiazide and loop diuretics are considered separately since their mechanisms action differ; thiazide diuretics inhibit the sodium-chloride cotransporter (*SLC12A3*) in the renal distal convoluted tubule whereas loop diuretics inhibit the sodium-potassium-chloride cotransporter (*SLC17A3*) in the thick ascending loop of Henle.^[@R18]^ These analyses may identify biologic pathways that contribute to adverse metabolic side effects from diuretic therapy.

Materials and Methods {#S2}
=====================

Study samples, phenotype, and genotype data {#S3}
-------------------------------------------

Data from 14 EA and 7 AA cohorts was used. [Table 1](#T1){ref-type="table"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"} provide summary characteristics of these cohorts; a detailed description is provided in the [Supplementary Materials](#SD1){ref-type="supplementary-material"}. Each study obtained informed consent from participants and approval from the appropriate institutional review boards. Genotyping was performed using Illumina (San Diego, CA, USA) or Affymetrix (Santa Clara, CA, USA) genotyping arrays. All studies performed imputation using HapMap Phase II data (release 22, build 36) except for the WHI cohorts which used the 1000 Genomes Project^[@R19]^ data. Imputation software packages used included MACH,^[@R20]^ Minimac,^[@R21]^ IMPUTE2,^[@R22]^ or BEAGLE^[@R23]^. Information on genotype and imputation for each study is presented in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

In total, 49,635 subjects over 18 years of age with genotype, phenotype, and covariate information were available in this analysis. Both longitudinal and cross-sectional studies were used, and all available data for each subject was used. In longitudinal cohorts that had multiple clinic visits for each subject, those multiple measurements (obtained across clinic visits) were used in the analysis. In cross-sectional studies that had only a single visit for each subject, a single measurement was used. Phlebotomy was performed to measure blood lipids after a minimum 8-hour fast as per individual study protocols. Three fasting lipid traits were considered for analyses: TG, HDL, and LDL (all mmol/L). LDL was calculated via the Friedewald equation (LDL=TC-HDL- \[TG/5\]) for those with TG ≤4.52 mmol/L.^[@R24]^ If TG \>4.52 mmol/L, LDL was set to missing unless directly assayed. LDL concentrations were adjusted for statin use as described elsewhere.^[@R25]^ TG concentrations were natural log-transformed for analysis.

Two patterns of diuretic exposure were used: 1) thiazide and thiazide-like diuretic use (yes/no) without use of loop; and 2) loop diuretic use (yes/no) without use of thiazide or thiazide-like diuretics. For each diuretic exposure, the unexposed group consisted of individuals taking neither diuretic. Drug use (yes/no) was defined as the use of any drug in the drug class, regardless of dosage, and with or without the use of a potassium supplement, as determined by self-report and/or inventory of medication bottles at each clinic visit. Examples of thiazide diuretic, loop diuretic, and statin medications are listed in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}.

Statistical analyses {#S4}
--------------------

To determine the association of SNV-diuretic interactions on blood cholesterol and TG concentrations, the following regression model $$\left. \mathbb{E}\lbrack Y \middle| {D,}\ {G,}\ C\rbrack = \ \beta_{0} + \ \beta_{D}D\  + \ \beta_{G}G + \ \beta_{GD}G \times D + \beta_{C}C \right.$$ was applied. Y is the fasting lipid value, D is the diuretic use (coded 0/1 for the absence/presence of the diuretic), G is the dosage of the imputed genetic variant coded additively (from 0 to 2), and C is the vector of all other covariates, which include age, sex, body mass index (BMI), principal components (to account for population stratification and admixture), and additional cohort-specific covariates (if any). Subjects with missing data for fasting (≥ 8 hours) lipid values, diuretic use, or any covariate were excluded from analysis. Subjects taking both thiazide and loop diuretics were also excluded from analysis.

Each study conducted GWAS analysis and provided the estimated SNV-diuretic interaction effect β~GD~ and standard error. For longitudinal cohorts with repeated measures, generalized estimating equations (GEE) with an independent working correlation were used with an *R* package *boss*; for studies with cross-sectional data, linear regression was used. To account for relatedness in families, family studies used either GEE treating each family as a cluster using *R* software or the linear mixed effect model approach with a random polygenic component (for which the covariance matrix depends on the kinship matrix) using ProbABEL ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). When minor allele counts of SNVs among participants on the diuretic were small (\< 10), the standardized interaction effect (β~GD~/SE) is not normally distributed. Note that, although a normal distribution is often appropriate in a large sample (and/or main effect analysis of GWAS), it is not appropriate in a GxE interaction study. Therefore, following our earlier work,^[@R26]^ cohort-specific *P-*values were computed based on a Student's t-distribution. The degrees of freedom for the t-distribution depend on the number of drug-exposed participants (N_exposed), the SNV imputation quality, and the minor allele frequency. Before meta-analysis, SNVs were excluded if 2 • MAF • N_exposed • imputation quality measure \< 10 to exclude unstable cohort-specific results that reflect small sample size, low MAF, or low imputation quality measures. As shown in Sitlani, et al.,^[@R27]^ we observed that this threshold provides a good balance between over-filtering and under-filtering.

Meta-analysis for each ancestry group was performed to combine these cohort-specific *P-*values with weighted Z-statistics using METAL,^[@R28]^ where weights were based on the number of drug-exposed subjects multiplied by the SNV imputation quality. As cohort-specific *P*-values were computed based on t distribution, inverse-variance weighted meta-analysis was not used. After meta-analysis, SNVs were excluded if heterogeneity *P* \< 1×10^−6^ or they were available in fewer than three cohorts for EA results or two cohorts for AA results. The ancestry-specific results were further combined to perform trans-ancestry meta-analysis using MANTRA (Meta-ANalysis of TRansethnic Association studies).^[@R29]^ MANTRA accounts for similarity in allelic effects among closely-related populations, while allowing for heterogeneity across populations with more diverse ancestries. As MANTRA uses a Bayesian framework, a traditional fixed-effect meta-analysis with weighted Z-statistics was also performed using METAL.

Genome-wide significance was defined as *P* \< 5×10^−8^ from METAL with a fixed-effect meta-analysis or Bayes Factor \>10^6^ from MANTRA. Suggestive evidence of association was defined as *P* \< 1×10^−6^ from METAL or Bayes Factor \>10^5^ from MANTRA. To assess type I error due to population stratification and other factors, quantile-quantile (QQ) plots were examined for all cohort-specific GWAS results for each pair of lipid and diuretic exposure. In addition, during meta-analysis, genomic control correction^[@R30]^ was applied to cohort-specific GWAS results if their genomic control lambda value was greater than 1. The gene locations referenced in the text and tables were obtained from the National Center for Biotechnology Information dbSNP database (reference assembly GRCh38.p2). Functional annotation information was sought using HaploReg^[@R31]^ and RegulomeDB.^[@R32]^

Results {#S5}
=======

The European-ancestry (EA) group included 39,710 subjects from 14 cohorts; the African-ancestry (AA) group included 9,925 subjects from 7 cohorts ([Table 1](#T1){ref-type="table"}). The number of subjects exposed to loop diuretics was 2,117 (5.3%) in EA and 784 (7.9%) in AA; the number exposed to thiazide and thiazide-like diuretics was 6,878 (17.3%) in EA and 3,923 (39.5%) in AA.

The QQ plots ([Supplementary Figures 1](#SD1){ref-type="supplementary-material"}--[6](#SD1){ref-type="supplementary-material"}) showed moderate inflation, in particular for the SNV-loop diuretic interaction terms for TG, LDL, and HDL analyses. The *P*-values based on a t-distribution (red crosses) that we used for our meta-analyses have better genomic control values than the *P*-values based on a standard normal distribution (black circles). Manhattan plots show the adjusted -log~10~(*P*) values for loop diuretics ([Figures 1](#F1){ref-type="fig"} and [Supplementary Figures 7](#SD1){ref-type="supplementary-material"}--[8](#SD1){ref-type="supplementary-material"}) and thiazide diuretics ([Supplementary Figures 9](#SD1){ref-type="supplementary-material"}--[11](#SD1){ref-type="supplementary-material"}) for TG, HDL, and LDL, respectively. Each figure includes plots of EA and AA separately, and for trans-ancestry meta-analysis using METAL and MANTRA. The SNVs reaching genome-wide significance (*P* \< 5×10^−8^) for association with gene-medication interactions on TG concentration are shown in [Table 2](#T2){ref-type="table"}. [Supplementary Table 4](#SD1){ref-type="supplementary-material"} shows the SNVs with suggestive evidence of SNV-diuretic interactions on each lipid trait (with *P* \< 10^−6^ from METAL or Bayes Factor \>10^5^ from MANTRA).

Loop diuretics with blood triglyceride (TG) {#S6}
-------------------------------------------

Analysis of the EA data identified two loci with genome-wide significant SNV-loop diuretic interaction effects (*P* \< 5×10^−8^) on log-transformed TG concentrations ([Figure 1](#F1){ref-type="fig"}). Another 8 loci demonstrated a suggestive association (*P* \< 1×10^−6^). The locus with the strongest evidence of association included a six-SNV cluster (most significant rs1463034, *P* = 1.91×10^−9^, β~GD~ = 0.0012 ± 0.0002 mmol/L) spanning four introns (7,256 bp) in ***COL11A1*** on chromosome 1 ([Figure 2A](#F2){ref-type="fig"}). A suggestive locus included a six-SNV cluster spanning a single intron (18,804 bp) on chromosome 10 in ***KIAA1217*** (most significant rs7077598, *P* = 7.48×10^−7^). Another suggestive locus of 11 SNVs was found on chromosome 10 which is approximately 145 kb downstream of ***DKK1*** (most significant rs10762762, *P* = 1.12×10^−7^). Within this locus, rs1441122 (*P* = 9.86×10^−7^) showed moderate evidence of altering the binding motif for the transcription factor ***TRIM28*** in a human embryonic kidney cell line (RegulomeDB Score 3a, <http://www.regulomedb.org/>).

Analysis of the AA data identified one locus with genome-wide significant interaction effects on TG concentrations, with two additional loci with suggestive *P*-values ([Figure 1](#F1){ref-type="fig"}). This 9-SNV locus (most significant rs6054018, *P* = 1.70×10^−10^, β~GD~ = 0.0024 ± 0.0003 mmol/L; [Figure 2B](#F2){ref-type="fig"}) is in an intergenic region on chromosome 20 approximately 500 kb upstream of ***BMP2*** and approximately 114 kb downstream of ***FERMT1***.

Trans-ancestry association tests strengthened evidence of association for the ***KIAA1217*** locus, elevating two of the six SNVs in this locus from suggestive in EA to genome-wide significance. In particular, at rs10508671, the SNV-loop diuretic interaction effect (β~GD~) was consistent in both ancestries (−0.0011 vs −0.0010 mmol/L, [Supplementary Table 4](#SD1){ref-type="supplementary-material"}), and therefore trans-ancestry test provided stronger evidence of association (EA *P* = 9.43×10^−7^, AA *P* = 0.002, trans-ancestry *P* = 1.08×10^−8^, MANTRA log~10~\[BF\] = 6.23, [Figure 2C](#F2){ref-type="fig"}). MANTRA also strengthened the association for a locus on chromosome 8 (most significant rs6985929, EA *P* = 8.86×10^−5^, trans-ancestry *P* = 1.02×10^−5^, MANTRA log~10~\[BF\] = 6.17) that overlaps an intron in ***BAALC*** and that is approximately 32 kb upstream of ***FZD6***. Notably, the effect sizes of SNV-loop diuretic interactions is small (ranging from 0.0010--0.0025 mmol/L, [Table 2](#T2){ref-type="table"}), and were greater for AA than for EA or trans-ancestry analyses.

Loop diuretics with blood HDL and LDL {#S7}
-------------------------------------

No loci reached genome-wide significance for SNV-loop diuretic interactions on HDL or LDL concentrations in the analyses of EA data. Suggestive association was noted with 11 SNVs in ***U6*** (rs203202, *P* = 1.65×10^−7^) for LDL. For LDL analyses in AA ([Supplementary Figure 8](#SD1){ref-type="supplementary-material"}), one SNV on chromosome 6 approximately 35 kb 5' of ***PHIP*** reached genome-wide significance (rs12208017, *P* = 3.73×10^−8^, β~GD~ = 0.3538 ± 0.0638 mmol/L); this SNV is in an expression quantitative trait locus (eQTL) for both ***PHIP*** and the adjacent gene, ***IRAK1BP1***. An additional SNV with a suggestive association (rs1312663, *P* = 4.06×10^−7^) is located approximately 100 kb upstream of ***SLC24A4***. Trans-ancestry analyses newly identified two SNVs in two loci with suggestive interaction associations on HDL, including a SNV on chromosome 11 in ***TEAD1*** (rs7924536, *P* = 5.79×10^−7^, MANTRA log~10~\[BF\] = 5.04).

Thiazide diuretics with blood TG, HDL and LDL {#S8}
---------------------------------------------

For analyses of SNV-thiazide diuretic interactions in EA and AA, no loci reached genome-wide significance for TG, HDL, or LDL ([Supplementary Figures 9](#SD1){ref-type="supplementary-material"}--[11](#SD1){ref-type="supplementary-material"}). In EA, suggestive association was noted with two loci including ***MYO16*** (rs1926511, *P* = 1.01×10^−7^) for TG and one locus for LDL. In AA, three loci yielded suggestive associations with HDL including a seven-SNV locus on chromosome 14 in ***TRIP11*** (most significant rs10083510, *P* = 3.20×10^−7^). SNVs in this locus are eQTLs for ***FBLN5***.

In trans-ancestry analyses, a single intronic SNV on chromosome 20 in ***MACROD2*** (rs6043629, *P* = 1.12×10^−8^, β~GD~ = 0.0382 ± 0.0068 mmol/L, MANTRA log~10~\[BF\] = 6.62) reached genome-wide significance for a thiazide diuretic interaction association on HDL; the strength of the association in EA (*P* = 1.25×10^−5^) and AA (*P* = 1.82×10^−4^) cohorts analyzed separately were much lower. With analysis of SNV-thiazide interactions on LDL, four SNVs on chromosome 17 in ***KIAA0753*** showed suggestive association in trans-ancestry (most significant rs2304976, *P* = 1.31×10^−7^, MANTRA log~10~\[BF\] = 5.34) although neither SNV approached significance in separate EA and AA analyses.

Discussion {#S9}
==========

Genome-wide meta-analyses with 39,710 European-ancestry (EA) individuals and 9,925 African-ancestry (AA) individuals were performed to identify genetic variants that modify the effect of loop or thiazide diuretic use on blood lipid concentrations. As the effects of loop and thiazide diuretic classes on lipids may differ,^[@R5],[@R6]^ each with different effects on renal sodium excretion,^[@R18]^ analyses were performed on each of diuretic classes separately. Ancestry-specific analyses (of EA and AA data) identified genome-wide significant variants in three loci with SNV-loop diuretic interaction on TG concentrations; trans-ancestry analysis strengthened evidence of association at two additional loci.

The most significant associations with TG concentrations in EA were observed at intronic SNVs clustered in ***COL11A1*** (collagen, type XI, alpha 1) on chromosome 1. ***COL11A1*** produces a structural/adhesion protein secreted by primary rat adipocytes.^[@R33]^ The expression of this gene is up-regulated during human adipogenesis,^[@R34]^ suggesting a role in the modulation of lipid traits. Although it remains unclear how diuretics modulate the effect of ***COL11A1*** variants on lipid traits, a ***COL11A1*** mutation has been shown to be associated with nephrogenic diabetes insipidus,^[@R35]^ which is characterized by an inability of the kidney to concentrate urine, thus providing a possible mechanistic link between ***COL11A1***, diuretics, and lipids.

Trans-ancestry analysis combining European and African results provided evidence of association at intronic SNVs clustered in ***KIAA1217*** (an uncharacterized long coding DNA) which are just 5' to an intronic microRNA (***MIR603***) on chromosome 10. ***KIAA1217*** variants have been associated with obesity.^[@R36]^ ***MIR603*** has been associated with benign and malignant tumors.^[@R37]--[@R40]^ Of potential interest, SNVs in both ***KIAA1217*** and ***COL11A1*** have been associated with lumbar disk herniation which, in turn, has been associated with blood lipid concentrations^[@R41]^ and cardiovascular risk traits and disease.^[@R42]^

Loci with genome-wide significant associations found in intragenic regions may impact the transcription of genes tens or hundreds of kilobases away from their target genes.^[@R43]^ The cluster of SNVs on chromosome 20 reaching genome-wide significance for TG in AA lies between two genes. ***FERMT1*** (fermitin family member 1) is a membrane-associated protein that links intracellular structural proteins to the extracellular matrix. While mutations in this gene have been implicated in a heritable skin disorder,^[@R44]^ connections to cardiovascular traits are sparse. Perhaps more relevant is this locus' proximity to ***BMP2*** (bone morphogenetic protein 2), the expression of which is regulated by angiotensin II,^[@R45]^ a key regulator of blood pressure and fluid/electrolyte balance. Furthermore, ***BMP2***, a member of the transforming growth factor (TGF)-β superfamily of cytokines, is expressed in endothelial cells, and has been shown to stimulate adjacent smooth muscle and endothelial cells to proliferate, differentiate, and deposit extra-cellular matrix, thus affecting blood pressure and contributing to atherosclerosis by processes that also includes Wnt signaling.^[@R46]^ ***BMP2*** also participates in the differentiation of mesenchymal stem cells to mature adipocytes,^[@R47]^ thus potentially affecting blood lipid concentrations. Variants in the BMP2 receptor gene (*BMPR2*) have also been implicated in familial forms of pulmonary arterial hypertension.^[@R48]^

A cluster of SNVs spanning the 3' end and intragenic region adjacent to ***BAALC*** and 5' of ***FZD6*** was nominally associated with TG response to loop diuretic therapy in both races; however, trans-ancestry meta-analysis by METAL and MANTRA strengthened the association. There is little evidence to link ***BAALC*** (brain and acute leukemia, cytoplasmic) with TG concentrations. However, both ***FZD6*** (frizzled class receptor 6), which is approximately 32 kb downstream from this locus on chromosome 8, and ***DKK1*** (dickkopf WNT signaling pathway inhibitor 1), included in a suggestive locus on chromosome 10, are negative regulars of the β-catenin/Wnt signaling cascade^[@R49],[@R50]^ that not only alters the expression of genes which regulate renal sodium, chloride and potassium handling,^[@R51]^ but is inhibited by the loop diuretic ethacrynic acid.^[@R52]^ Both ***FZD6*** and ***DKK1*** have also been associated with renal development,^[@R53],[@R54]^ glomerular damage, and proteinuria.^[@R55],[@R56]^

Trans-ancestry analyses identified SNVs in ***TEAD1*** (TEA domain family member 1 \[SV40 transcriptional enhancer factor\]) as significantly associated with HDL concentrations. This transcription factor is another β-catenin/Wnt pathway member^[@R57]^ that has been shown to modulate adipocyte differentiation and proliferation^[@R58]^ and play a role in regulating insulin sensitivity via skeletal muscle fiber type switching.^[@R59],[@R60]^

In the analyses of SNV-loop diuretic interactions in AA data with LDL, a SNV reaching genome-wide significance adjacent to ***PHIP*** (pleckstrin homology domain interacting protein) is within 270 kb of another SNV (rs16890334) previously identified as having a genome-wide significant association with blood pressure response to a high-sodium diet intervention in Han Chinese.^[@R61]^

No loci from analyses of thiazide and thiazide-like diuretics with lipid traits reached genome-wide significance in EA or AA. However, trans-ancestry analyses identified a ***MACROD2*** (MACRO domain containing 2) with genome-wide significance for a diuretic interaction effect on HDL. This gene was found to have a significant association with coronary artery disease and hypertension using a two-marker testing approach in a reanalysis of data from the Wellcome Trust Case Control Consortium,^[@R62]^ and a suggestive association with brain infarcts in another meta-analysis;^[@R63]^ however, the role of this gene in determining cardiovascular traits remain uncertain.

Limitations {#S10}
===========

Although this study identified interesting SNV-loop diuretic interactions as modulators of TG concentrations, there were limitations in this study. First, the study design assumed therapeutic class effects although individual drugs may have different effects on lipids.^[@R13],[@R64],[@R65]^ Information regarding the dosage, duration, or adequacy of diuretic therapy may have also affected the traits but were not available in most studies. Second, because potassium-sparing diuretics were frequently co-administered with thiazide and thiazide-like diuretics, it was not feasible to pursue the sole contributions of potassium-sparing diuretics in this study. Third, the effects of other classes of anti-hypertensive medications that may affect lipid levels, such as calcium, β-adrenergic, and α-adrenergic receptor blockers,^[@R66]^ were not assessed in this study. Fourth, the potential contribution of co-morbidities (e.g. diabetes, renal dysfunction) and lifestyle choices (e.g. alcohol consumption, physical activity) on lipid traits was not considered. Fifth, the relatively smaller number of AA subjects exposed to loop diuretics may have reduced the power to detect significant association or increased the risk for spurious findings in this ancestry group. Finally, given the number of tests performed and the relatively small effect sizes for the interactions, this effort should be construed as a discovery analysis that warrants replication.

Conclusions {#S11}
===========

This genome-wide SNV-diuretic interaction meta-analysis on blood lipid concentrations used data from 39,710 European-ancestry individuals and 9,925 African-ancestry individuals. The results of the present study suggest stronger interaction effects for loop versus thiazide diuretics, identifying several genome-wide significant loci of small effect sizes. The results of this study are typical of most GWAS studies wherein loci of small-to-modest effects are identified.^[@R67]--[@R77]^ Although these loci are likely not action able in terms of genotype-guided therapy, some may nonetheless be biologically and clinically relevant,^[@R78]^ perhaps by identifying biologic pathways that contribute to adverse metabolic side effects from diuretic therapy. These findings may also explain, at least in part, some of the residual CVD risk following reduction of blood pressure in patients treated with anti-hypertensive medications.
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![Manhattan plots for analysis of SNV-loop diuretic interaction on triglyceride concentrations. The ancestry-specific meta-analysis used 11 cohorts of European ancestry (upper-left panel) and 6 cohorts of African ancestry (lower-left panel). Trans-ancestry meta-analysis used fixed-effect weighted Z-statistics with METAL (upper-right panel) and a Bayesian framework with MANTRA (lower-right panel). The -log~10~(*P*) from METAL or log~10~(*Bayes Factor*) from MANTRA was plotted at the chromosomal location of each variant. Manhattan plots for the remaining lipid-diuretic pairs are shown in [Supplementary Figures 7](#SD1){ref-type="supplementary-material"}--[11](#SD1){ref-type="supplementary-material"}.](nihms-1544186-f0001){#F1}

![Regional plots of significant SNV-loop diuretic interaction effects on triglyceride concentrations on chromosome 1 in European ancestry (top), chromosome 20 in African ancestry (middle), and chromosome 10 in trans-ancestry analyses of European and African ancestries (bottom). Plots were created using LocusZoom software (<http://csg.sph.umich.edu/locuszoom/>). Linkage disequilibrium (LD, r^2^) was based on hg19/1000 Genomes Nov 2014 EUR for EA and AFR hg19/1000 Genomes Nov 2014 for AA. Because no LD information was available for trans-ancestry results combining EA and AA results, the bottom plot does not show LD.](nihms-1544186-f0002){#F2}

###### 

Baseline characteristics of 21 participating cohorts of European and African ancestry. Seventeen cohorts were used for loop diuretic analysis.

  -------------------------------------------------------------------------------
  Ancestry                 Study   N       Loop\      Thiazide\     TG\
                                           Exposed\   Exposed\      (Mean & SD)
                                           Subjects   Subjects      
  ------------------------ ------- ------- ---------- ------------- -------------
  European                 AGES    1,677   153        466           1.17 (0.57)

  ARIC                     8,881   179     1,179      1.55 (1.03)   

  CHS                      3,174   218     838        1.58 (0.85)   

  FHS                      7,068   163     567        1.48 (1.17)   

  Health ABC               1,828   130     329        1.73 (1.00)   

  HVH1                     440     51      167        2.25 (1.29)   

  HVH2                     192     21      80         2.36 (1.96)   

  HyperGEN                 1,187   44      196        1.87 (1.31)   

  MESA                     2,359   NA      563        1.49 (1.02)   

  PROSPER                  4,592   618     1,402      1.52 (0.70)   

  RS1                      3,421   269     405        1.38 (0.61)   

  RS2                      2,096   86      147        1.40 (0.64)   

  WHI CT GARNET Baseline   1,222   24      142        1.65 (0.86)   

  WHI CT GARNET Core       861     15      78         1.66 (0.81)   

  African                  ARIC    2,119   45         655           1.26 (0.86)

  CHS                      709     104     250        1.30 (0.71)   

  HyperGEN                 1,110   86      278        1.17 (0.77)   

  JHS                      1,500   91      381        1.20 (0.96)   

  WHI CT SHARe Baseline    3,636   150     752        1.26 (0.76)   

  WHI CT SHARe Core        801     34      176        1.35 (0.64)   

  WHI OS SHARe Baseline    3,628   206     843        1.27 (0.77)   
  -------------------------------------------------------------------------------

BMI, body mass index (kg/m2); DBP, diastolic blood pressure (mmHg); SBP, systolic blood pressure (mmHg); TG, triglycerides (mmol/L).

###### 

SNVs with genome-wide significant (with P \< 5×10^−8^ from METAL or Bayes factor \>10^6^ from MANTRA) SNV-loop diuretic interactions on triglyceride concentrations identified from European-ancestry, African-ancestry, and trans-ancestry analyses.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker       Chr   Position      Alleles   European Ancestry   African Ancestry   Trans Ancestry   Mantra   Neighboring\                                                                                       
                                                                                                              Genes                                                                                              
  ------------ ----- ------------- --------- ------------------- ------------------ ---------------- -------- -------------- -------------- -------- -------- ------ -------------- -------- -------- ---------- ------------------------------------------
  rs1463034    1     103,227,805   t/c       0.92                **1.91E-09**       0.0126           0.0003   0.59           4.40E-01       0.0111   0.0003   0.83   2.27E-06       0.0121   0.0001   5.54       ***COL11A1***

  rs1870958    1     103,229,744   t/g       0.92                **2.57E-09**       0.0126           0.0003   0.59           5.00E-01       0.0111   0.0003   0.82   4.01E-06       0.0121   0.0001   **6.53**   

  rs2786125    1     103,235,061   a/g       0.06                **1.94E-08**       0.0100           0.0002   0.31           4.37E-01       0.0115   0.0003   0.14   2.18E-05       0.0105   0.0002   5.68       

  rs2622870    1     103,236,564   t/g       0.94                **1.98E-08**       0.0127           0.0003   0.69           3.40E-01       0.0110   0.0003   0.87   2.14E-05       0.0122   0.0002   **6.14**   

  rs2622874    1     103,239,505   a/c       0.06                **1.93E-08**       0.0100           0.0002   0.31           3.26E-01       0.0116   0.0003   0.13   2.31E-05       0.0104   0.0002   **6.77**   

                                                                                                                                                                                                                 

  rs7607797    2     117,944,672   t/c       0.97                **3.60E-08**       0.0127           0.0003   0.66           4.62E-01       0.0111   0.0003   0.86   6.88E-05       0.0121   0.0002   3.51       *DDX18*

                                                                                                                                                                                                                 

  rs7002454    8     104,347,955   t/c       0.95                8.78E-05           0.0124           0.0002   0.87           3.58E-02       0.0122   0.0005   0.93   1.10E-05       0.0124   0.0002   **6.10**   ***BAALC*** */ FZD6*

  rs6985929    8     104,348,009   a/g       0.95                8.86E-05           0.0124           0.0002   0.87           3.29E-02       0.0124   0.0005   0.93   1.02E-05       0.0124   0.0002   **6.17**   

                                                                                                                                                                                                                 

  rs10508671   10    24,574,062    t/c       0.03                9.43E-07           0.0102           0.0002   0.25           2.12E-03       0.0103   0.0003   0.11   **1.07E-08**   0.0102   0.0002   **6.23**   ***KIAA1217*** */ MIR603 / ARHGAP21*

  rs10508672   10    24,574,441    a/g       0.03                9.52E-07           0.0102           0.0002   0.24           2.32E-03       0.0103   0.0003   0.11   **1.18E-08**   0.0102   0.0002   **6.20**   

                                                                                                                                                                                                                 

  rs3852940    20    6,165,600     a/g       0.79                6.78E-01           0.0112           0.0002   0.70           **1.18E-08**   0.0132   0.0004   0.77   1.09E-02       0.0116   0.0001   5.73       *CRLS1 / LRRN4 / FERMT1 / CASC20 / BMP2*

  rs6054016    20    6,174,368     t/c       0.06                6.06E-01           0.0114           0.0003   0.19           **4.06E-10**   0.0092   0.0003   0.10   2.15E-03       0.0103   0.0002   **7.84**   

  rs6054018    20    6,175,236     t/g       0.94                6.12E-01           0.0112           0.0003   0.80           **1.70E-10**   0.0139   0.0004   0.90   1.83E-03       0.0124   0.0002   **7.60**   

  rs8120588    20    6,178,849     t/c       0.94                6.24E-01           0.0112           0.0003   0.81           **3.75E-10**   0.0139   0.0004   0.90   1.88E-03       0.0124   0.0002   **7.99**   

  rs7348828    20    6,182,498     a/g       0.94                6.38E-01           0.0112           0.0003   0.81           **3.56E-10**   0.0139   0.0004   0.90   1.75E-03       0.0124   0.0002   **6.60**   

  rs8122198    20    6,186,686     t/c       0.94                8.99E-01           0.0113           0.0003   0.85           **9.53E-09**   0.0141   0.0006   0.91   2.46E-03       0.0122   0.0002   **6.29**   

  rs6054037    20    6,187,877     c/g       0.94                8.69E-01           0.0113           0.0003   0.85           **9.94E-09**   0.0141   0.0006   0.91   2.73E-03       0.0122   0.0002   **6.43**   

  rs6038400    20    6,188,201     a/c       0.06                8.66E-01           0.0113           0.0003   0.15           **1.03E-08**   0.0091   0.0004   0.09   2.78E-03       0.0104   0.0002   5.08       

  rs3852942    20    6,192,559     a/g       0.06                8.71E-01           0.0113           0.0003   0.17           **3.36E-08**   0.0093   0.0003   0.10   3.46E-03       0.0104   0.0002   4.53       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Covariates included in the analysis: age, sex, BMI, principal components, and additional cohort-specific covariates (if any). Abbreviations: Chr, chromosome, Freq, frequency of allele 1. **Bolded** genes include intragenic SNVs. **Bolded** P-values and MANTRA log~10~BF identify values that are genome-wide significant. Units for Effect (SE) is mmol/L.
